Octane Medical acquires B. Braun’s global orthobiologics business
octane news
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category.
The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to produce the graft using the Cocoon bioreactor – Octane inventions that enable the automated synthetic production of living tissue from a patient’s cells for use as orthopedic implants in bone, cartilage or tendon reconstruction.
“We are honoured to be recognized by the Edison Awards,” says Octane CEO Tim Smith. “It’s yet another validation of the great work our scientists do here at Octane, and it inspires us even more to drive our vision of making regenerative medicine the standard of care.”
With AUTOGRAFTA, donor cells removed from a patient are engineered within the automated bioreactor environment of Cocoon to produce a living implant that regenerates original biological function without negative side effects. This innovative combination of advanced implant technology and automated production elevates tissue engineering to a commercial scale.
“AUTOGRAFTA and Cocoon restore the natural function of damaged tissues without implanting unnatural metallic and plastic hardware,” says Smith. “The result is lasting natural recovery without the worries around long-term implant rejection and complex secondary surgeries.”
For press inquiries please contact Renee Thibodeau
renee.thibodeau@octaneco.com
613-634-6345 x200
The Edison Awards is the world’s most revered Innovation Award dedicated to recognizing and honoring the best in innovation and innovators since 1987. For more information about the Edison Awards complete program and a list of past winners, visit www.edisonawards.com
Media Contact
Lauren Masselli
207.890.3747
lauren@edisonawards.com
Cocoon™ is a patient-scale cell therapy system that forms the core of a series of versatile cell and tissue therapy production systems. Unlike other bioreactor systems, this platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation – all in a closed, single-use disposable cassette.
Coupled with advanced bioreactors, biosensor feedback and innovative cell scaffolds, this cell culture and tissue engineering platform opens up an array of clinical applications. Cocoon is an integrated turnkey production solution that can be configured as a compact but powerful system with a small footprint, or as a multi-patient system for ultra-efficient, enterprise-level deployment. Please read more about Cocoon and our other innovations in regenerative medicine .
Kingston, Ontario, Canada / Melsungen, Germany, June 5th, 2024 – Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine.
June 5, 2024
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
March 2, 2022
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada. The 40,000-square-foot building, which Octane purchased in 2011, houses the company's head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a ...
December 15, 2020
Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane ...
October 29, 2018
